Cortexyme (CRTX) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Cortexyme (CRTXResearch Report) today and set a price target of $15.00. The company’s shares closed last Monday at $6.08, close to its 52-week low of $3.79.

According to TipRanks.com, Fein has 0 stars on 0-5 stars ranking scale with an average return of -4.8% and a 36.7% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Deciphera Pharmaceuticals.

Cortexyme has an analyst consensus of Moderate Buy, with a price target consensus of $13.50.

See Insiders’ Hot Stocks on TipRanks >>

Based on Cortexyme’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $21.71 million. In comparison, last year the company had a GAAP net loss of $20.56 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cortexyme, Inc. is a biopharmaceutical company, which develops therapeutics based on data supporting a new theory of the cause of Alzheimer’s and other neurodegenerative disorders. Its product, COR388, is in clinical trial. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.

Read More on CRTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More